PRODUCT CODE: ET1705-57

Pyruvate Dehydrogenase E1 beta subunit Recombinant Rabbit Monoclonal Antibody [JM66-33] (ET1705-57)

  • Recombinant

Applications

  • WB

  • IHC-P

  • IP

  • FC

REACTIVITY

  • Human

  • Mouse

  • Rat

-
+
Western blot analysis of Pyruvate Dehydrogenase E1 beta subunit on HepG2 (1) and Hela (2) cell lysate using anti-Pyruvate Dehydrogenase E1 beta subunit antibody at 1/1,000 dilution.
  • Western blot analysis of Pyruvate Dehydrogenase E1 beta subunit on HepG2 (1) and Hela (2) cell lysate using anti-Pyruvate Dehydrogenase E1 beta subunit antibody at 1/1,000 dilution.
  • Western blot analysis of Pyruvate Dehydrogenase E1 beta subunit on mouse kidney tissue (1) and PC-12 (2) cell lysate using anti-Pyruvate Dehydrogenase E1 beta subunit antibody at 1/1,000 dilution.
  • Immunohistochemical analysis of paraffin-embedded rat heart tissue using anti-Pyruvate Dehydrogenase E1 beta subunit antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human stomach cancer tissue using anti-Pyruvate Dehydrogenase E1 beta subunit antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-Pyruvate Dehydrogenase E1 beta subunit antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded mouse brain tissue using anti-Pyruvate Dehydrogenase E1 beta subunit antibody. Counter stained with hematoxylin.
  • Immunohistochemical analysis of paraffin-embedded mouse hippocampus tissue using anti-Pyruvate Dehydrogenase E1 beta subunit antibody. Counter stained with hematoxylin.
  • Flow cytometric analysis of Hela cells with Pyruvate Dehydrogenase E1 beta subunit antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Western blot analysis of Pyruvate Dehydrogenase E1 beta subunit on HepG2 (1) and Hela (2) cell lysate using anti-Pyruvate Dehydrogenase E1 beta subunit antibody at 1/1,000 dilution.

Applications

  • WB

  • IHC-P

  • IP

  • FC

REACTIVITY

  • Human

  • Mouse

  • Rat

SPECIFICATIONS

Product Type

Recombinant Rabbit monoclonal primary

Product Name

Pyruvate Dehydrogenase E1 beta subunit Recombinant Rabbit Monoclonal Antibody [JM66-33] (ET1705-57)

Immunogen

Recombinant protein

Host

Rabbit

Positive Control

HepG2, Hela, PC-12, mouse kidney, rat heart tissue, human kidney tissue, human stomach cancer tissue, mouse hippocampus tissue, mouse brain tissue.

Conjugation

Unconjugated

Clonality

Monoclonal

Clone Number

JM66-33

PROPERTIES

Form

Liquid

Storage Condition

Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.

Storage Buffer

1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

1 ug/ul

PURIFICATION

Protein A purified.

Isotype

IgG

APPLICATION DILUTION

  • WB

  • 1:500-1:2,000

  • IHC-P

  • 1:50-1:200

  • FC

  • 1:50-1:100

TARGET

UNIPROT #

PROTEIN NAME

Pyruvate Dehydrogenase E1 beta subunit

SYNONYMS

DKFZp564K0164 antibody; mitochondrial antibody; ODPB_HUMAN antibody; pdhB antibody; PDHBD antibody; PDHE1 B antibody; PDHE1-B antibody; PHE1B antibody; Pyruvate dehydrogenase (lipoamide) beta antibody; Pyruvate dehydrogenase E1 beta polypeptide antibody; Pyruvate dehydrogenase E1 component subunit beta antibody; Pyruvate dehydrogenase E1 component subunit beta mitochondrial antibody

SUBCELLULAR LOCATION

Mitochondrion matrix.

FUNCTION

The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO. It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3). Defects in PDHB are a cause of pyruvate dehydrogenase E1 component deficiency (PDHE1 deficiency). PDHE1 deficiency is the most common enzyme defect in patients with primary lactic acidosis. It is associated with variable clinical phenotypes ranging from neonatal death to prolonged survival complicated by developmental delay, seizures, ataxia, apnea, and in some cases to an X-linked form of Leigh syndrome (LS) (Leigh encephalomyelopathy).